Damiański Piotr, Kuna Piotr, Panek Michał
The Clinical Department of Internal Diseases, Asthma and Allergies with the Pediatric Subdepartment, N. Barlicki University Teaching Hospital no. 1 in Lodz, Poland.
Pol Merkur Lekarski. 2019 Aug 30;47(278):70-71.
Although alpha-1 antitrypsin (A1AT) deficiency represents one of the most common genetically conditioned diseases in the population of Caucasian adult individuals, it is rarely diagnosed. Alpha-1 antitrypsin is an important component of the anti-proteolytic protection in the lungs. Individuals affected by the protein deficiency are exposed to a higher risk of developing chronic obstructive pulmonary disease (COPD), emphysema or liver diseases.
A 52-year-old farmer, non-smoker, spraying orchards since the age of 15 years, was admitted to the Department with dyspnea at rest and productive cough. He had a medical history of COPD, congestive heart failure, generalized emphysema of ten years' duration On admission the patient's general condition was satisfactory (fair). Physical examination showed symmetric expiratory wheezing over the upper and lower fields of the lungs with loss of vesicular murmur in the lower fields. Spirometry revealed a severe chronic bronchial obstruction, and an arterial blood gas test showed hypoxemia. Laboratory tests demonstrated an increased concentration of inflammatory markers. High resolution computed tomography (HRCT) of the chest showed evidence of generalized emphysema, bronchiectasis and exacerbation of peribronchial inflammatory changes. Intensive anti-inflammatory, bronchodilator treatment and antibiotic therapy were implemented, which resulted in an optimal improvement of the patient's condition. Based on the whole clinical picture A1AT deficiency was suspected. Alpha-1-antitrypsin deficiency, MZ phenotype, with 65 mg/dl concentration was diagnosed.
Diagnostic tests for alpha-1 antitrypsin deficiency should always be considered in patients with emphysema or symptomatic COPD identified at an early age. In the described case the period between occurrence of clinical signs and establishing the diagnosis was ten years, which proves that there is a strong need to spread knowledge on A1AT among medical professionals. Otherwise, most of the patients will lose their chance of modifying their lifestyle or receiving proper treatment that could prevent the progression of changes in the lungs.
尽管α-1抗胰蛋白酶(A1AT)缺乏症是白种人成年人群中最常见的遗传性疾病之一,但很少被诊断出来。α-1抗胰蛋白酶是肺部抗蛋白水解保护的重要组成部分。受该蛋白质缺乏影响的个体患慢性阻塞性肺疾病(COPD)、肺气肿或肝脏疾病的风险更高。
一名52岁的农民,不吸烟,自15岁起就从事果园喷洒工作,因静息时呼吸困难和咳痰入院。他有慢性阻塞性肺疾病、充血性心力衰竭病史,患广泛性肺气肿已达十年。入院时患者的一般状况良好(尚可)。体格检查显示双肺上下野对称的呼气性哮鸣音,下野肺泡呼吸音减弱。肺功能检查显示严重的慢性支气管阻塞,动脉血气分析显示低氧血症。实验室检查显示炎症标志物浓度升高。胸部高分辨率计算机断层扫描(HRCT)显示广泛性肺气肿、支气管扩张以及支气管周围炎症变化加重。实施了强化抗炎、支气管扩张剂治疗和抗生素治疗,患者病情得到了最佳改善。基于整体临床表现,怀疑为A1AT缺乏症。诊断为α-1抗胰蛋白酶缺乏症,MZ表型,浓度为65mg/dl。
对于早年确诊的肺气肿或有症状的慢性阻塞性肺疾病患者,应始终考虑进行α-1抗胰蛋白酶缺乏症的诊断检测。在所描述的病例中,从出现临床症状到确诊的时间间隔为十年,这证明非常有必要在医学专业人员中普及关于A1AT的知识。否则,大多数患者将失去改变生活方式或接受适当治疗的机会,而这些治疗本可预防肺部病变的进展。